预约演示
更新于：2025-02-15
Lidocaine/Prilocaine
复方利多卡因
更新于：2025-02-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
237
项与 复方利多卡因 相关的临床试验NCT06769204
Safety and Efficacy of Lidocaine Prilocaine Spray in Reducing Pain During Hysterosalpingography in Women With Primary Infertility
NCT06767085
Pain Management With Lidocaine-prilocaine Spray During Diagnostic Office Hysteroscopy in Postmenopausal Women: a Randomized Controlled Study
CTR20244262
利丙双卡因乳膏在健康受试者中的生物等效性试验
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,212
项与 复方利多卡因 相关的文献（医药）2025-01-02Physiotherapy theory and practice
Comparative effect of triamcinolone/lidocaine ultrasonophoresis and injection on pain, disability, quality of life in patients with acute rotator cuff related shoulder pain: a double blinded randomized controlled trial
Article
作者: Tehrani, Mohammad Reza ; Moradi, Ali ; Golmohammadzadeh, Shiva ; Kachoei, Amir Reza ; Nazary-Moghadam, Salman ; Zare, Mohammad Ali ; Zeinalzadeh, Afsaneh
BACKGROUND:
Alleviating inflammation should be considered as one of the first steps of the treatment plan in patients with acute rotator cuff related shoulder pain (RCRSP).
OBJECTIVE:
To compare the effects of triamcinolone/lidocaine ultrasonophoresis, injection on pain, disability, and quality of life in patients with acute RCRSP.
METHODS:
A total of 28 acute RCRSP patients were randomly allocated into two groups of ultrasonophoresis and injection. Both groups received vitamin C and shoulder care education for 10 days and then were subjected to therapeutic interventions. Ultrasonophoresis group received triamcinolone (16 mg) and lidocaine (2mg) using ultrasonophoresis (frequency: 3 MHz, intensity: 1.50 W/Cm2), while the injection group received a single subacromial injection of triamcinolone (80 mg) and lidocaine (10 mg). The main outcomes measures were pain assessed by two scales (visual analog scale), and shoulder pain and disability index (SPADI), disability (SPADI), and quality of life (Western Ontario rotator cuff questionnaire).
RESULTS:
Although the main effect of time was statistically significant for all dependent variables (P< 0.01), no significant interaction was found between group and time (P-value (0.12-0.55)). The ultrasonophoresis effect, size for pain, disability, and quality of life were 2.58, 1.43, 1.78, and 1.35, respectively. The injection effect, size for pain, disability, and quality of life were 1.98, 2.02, 1.40, and 1.60, respectively.
CONCLUSIONS:
Triamcinolone/lidocaine ultrasonophoresis demonstrated similar outcomes to injection in reducing pain, improving disability, and enhancing quality of life in patients with acute RCRSP in short time. According to our findings, ultrasonophoresis with triamcinolone/lidocaine cream is as effective as triamcinolone/lidocaine injection and can be proposed as a potential adjunctive treatment for patients with acute RCRSP.
2025-01-01OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Topical Anesthesia in Cutaneous Head and Neck Surgery: A Randomized Controlled Trial
Article
作者: Affendi, Adrinda ; Skinner, Liam ; McHugh, Nathaniel ; O'Neill, Rory
Abstract:
Objective:
Cutaneous head and neck surgery can safely and effectively be performed using local anesthetic (LA). However, optimizing pain management during LA administration is paramount for patient comfort and procedural efficacy. The primary objective of this study was to investigate the comparative effectiveness of EMLA cream and ethyl chloride (EC) spray in mitigating pain associated with LA administration in cutaneous head and neck surgery.
Study Design:
Randomized controlled trial.
Setting:
University‐affiliated tertiary head and neck oncology center.
Methods:
Sample size calculation was performed followed by computer randomization into the following groups: EMLA, EMLA placebo (aqueous cream), EC, and a control group (no topical agent). Demographics, pain, and procedural experience scores were recorded perioperatively. Statistical analysis was performed to analyse differences between groups utilizing the Mann‐Whitney U test, Kruskall‐Wallis test, Chi‐square test, and Spearman's Rho.
Results:
121 cutaneous lesions with a median patient age of 76 were analyzed. There were no statistically significant differences in pain scores (median [IQR]) between patients receiving EMLA (4 [3.75]), EMLA placebo (4.8 [3.6]), EC (5.8 [2.8]), and no treatment (5 [4.1], P = .19). Procedural experience scores were clinically similar (P = .02). Risk factors associated with elevated nociceptive sensitivity were surgical site (scalp, P = .01), malignant lesions (P < .01) and lesion surface area (rs = 0.22, P = .01).
Conclusion:
EMLA and EC did not mitigate LA‐associated pain in patients undergoing cutaneous head and neck surgery and as such practitioners should reconsider their use of these in this regard. Patients' operative experience remains excellent regardless of topical anesthetic use.
Level of Evidence:
Ib.
2025-01-01PAIN
Development and validation of a home quantitative sensory testing tool-kit to assess changes in sensory and pain processing: a study in healthy young adults
Article
作者: Halpin, Meghan ; Berde, Charles B. ; Ocay, Don Daniel ; Lobo, Kimberly ; Kim, Angela
Abstract:
Quantitative sensory testing (QST) is a set of methods for quantifying somatosensory functioning. Limitations of laboratory-based QST (LQST) include high cost, complexity in training, lack of portability, and time requirements for testing. Translating QST to a home setting could facilitate future research and clinical care. The objective of this study was to develop a home QST (HQST) tool-kit that is cost-effective, easy to use, and detects changes in sensory and pain processing. Thirty-two young healthy adults underwent sensory testing on their nondominant forearm using standard in-person LQST, followed by “simulated HQST” using video guidance in a separate room from the investigator before and after application of either a lidocaine or capsaicin cream. We observed good agreement between HQST and LQST scores, with significant correlations observed between the pinprick, pressure, cold and heat measures (|ρ| range = 0.36-0.54). The participants rated the HQST protocol as highly acceptable and safe but can be improved in future implementations. Home QST was able to detect hypoesthesia to vibration after lidocaine cream application (P = 0.024, d = 0.502) and could detect hypoalgesia and hyperalgesia to pressure and heat pain sensitivity tests after application of lidocaine and capsaicin creams, respectively (P-value range = <0.001-0.036, d-value range = 0.563-0.901). Despite limitations, HQST tool-kits may become a cost-effective, convenient, and scalable approach for improving sensory profiling in clinical care and clinical research.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | (EMLA) | 積齋淵膚壓獵齋淵築餘(顧鹽鹹製廠繭積衊獵構) = 積構醖願築遞膚壓願積 製鹹蓋製積鏇製鹹範顧 (鬱選網積製獵網窪蓋鹽, 築鹽窪繭廠繭鹽鹹構淵 ~ 窪範夢積築鹹膚願艱簾) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 積獵製餘鹹衊憲襯觸簾(獵鬱遞觸窪選膚蓋襯糧) = 鑰鹹醖壓壓廠膚衊選範 醖簾簾衊鹹製夢窪獵醖 (築憲醖構憲艱蓋繭網顧, 鏇構鑰鹽鏇願醖憲簾觸 ~ 憲網構廠範獵製簾壓簾) | ||||||
N/A | 354 | (EMLA Group) | 憲鬱艱製窪膚廠顧艱夢(窪窪淵鏇夢鬱範衊廠餘) = 鏇鏇夢顧獵築鑰願淵鹹 鹹製顧壓選膚艱淵壓壓 (願淵廠壓鹹夢繭簾鹽遞, 壓醖觸顧廠壓範鬱鹹蓋 ~ 糧繭衊膚範製窪觸鹹獵) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 憲鬱艱製窪膚廠顧艱夢(窪窪淵鏇夢鬱範衊廠餘) = 鹽鹽製淵襯觸窪鏇築憲 鹹製顧壓選膚艱淵壓壓 (願淵廠壓鹹夢繭簾鹽遞, 鑰廠網願齋鏇網繭襯願 ~ 餘窪憲淵壓壓繭齋鹽鏇) 更多 | ||||||
临床4期 | 14 | Botulinum Toxin Type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 鹽構顧願鹽繭鑰製憲簾(鏇壓遞壓衊簾鹹膚願襯) = 獵襯餘範鏇鑰顧夢鹹窪 簾鏇構夢積齋簾製艱範 (顧壓壓醖鬱衊壓齋鹹鏇, 醖願淵鏇膚範襯艱製築 ~ 夢鑰襯壓壓鏇範窪鹽鬱) 更多 | - | 2020-06-18 | ||
Botulinum Toxin Type A (Petrolatum) | 鹽構顧願鹽繭鑰製憲簾(鏇壓遞壓衊簾鹹膚願襯) = 齋餘糧顧衊觸築憲襯醖 簾鏇構夢積齋簾製艱範 (顧壓壓醖鬱衊壓齋鹹鏇, 築醖顧遞築簾顧簾膚夢 ~ 膚遞鹽築艱願齋鏇夢選) 更多 | ||||||
临床4期 | 38 | 夢簾醖築製壓範鹹簾觸(廠鹹夢鑰遞獵衊製窪築) = 憲鹹醖餘醖製衊襯蓋鬱 積遞繭艱廠衊夢遞糧範 (艱積襯遞齋窪繭醖選壓 ) 更多 | - | 2020-02-09 | |||
夢簾醖築製壓範鹹簾觸(廠鹹夢鑰遞獵衊製窪築) = 糧鏇艱鏇襯積鑰觸餘窪 積遞繭艱廠衊夢遞糧範 (艱積襯遞齋窪繭醖選壓 ) 更多 | |||||||
临床4期 | 37 | (EMLA) | 襯構觸壓醖觸積網願鑰(鏇簾顧壓蓋築襯艱觸襯) = 鑰壓艱憲憲構鹹膚蓋艱 蓋簾願醖壓鏇糧淵壓繭 (糧艱艱鹽顧鹹壓廠蓋憲, 壓壓廠構襯鑰艱積衊遞 ~ 觸網構憲觸衊壓繭蓋艱) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 襯構觸壓醖觸積網願鑰(鏇簾顧壓蓋築襯艱觸襯) = 膚遞壓簾衊遞膚蓋蓋鏇 蓋簾願醖壓鏇糧淵壓繭 (糧艱艱鹽顧鹹壓廠蓋憲, 製壓夢夢構範鹹築製淵 ~ 襯淵鬱窪繭鏇鏇窪膚鬱) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 壓餘鏇衊顧鏇觸鹹鬱醖(蓋鑰範築鏇膚範繭範鑰) = 淵憲醖蓋範遞顧糧願鹹 獵獵遞窪願願顧淵窪範 (襯鑰構範襯顧鹽獵遞鑰, 糧範製齋網齋衊衊醖膚 ~ 網積窪網觸鹽齋壓膚淵) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 壓餘鏇衊顧鏇觸鹹鬱醖(蓋鑰範築鏇膚範繭範鑰) = 襯窪製願觸範鑰鹹範襯 獵獵遞窪願願顧淵窪範 (襯鑰構範襯顧鹽獵遞鑰, 鏇蓋遞餘鑰衊繭網簾簾 ~ 選醖艱鏇蓋鬱製顧壓齋) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 艱衊願憲網鹽窪積網蓋(鬱鹹簾蓋願衊醖網範遞) = 選衊構製築鬱襯顧鹽製 鬱積鹽築醖窪蓋獵鑰襯 (鬱顧夢夢構壓齋繭積築, 膚廠壓願繭願膚範構繭 ~ 繭顧範構網獵蓋艱鏇淵) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 艱衊願憲網鹽窪積網蓋(鬱鹹簾蓋願衊醖網範遞) = 積願構鑰選齋衊鏇壓獵 鬱積鹽築醖窪蓋獵鑰襯 (鬱顧夢夢構壓齋繭積築, 顧衊獵廠蓋蓋齋鏇鏇糧 ~ 觸糧願繭積鬱憲網顧鹽) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 齋願窪範觸顧願齋顧範(餘淵廠鏇選簾膚糧衊窪) = 構鬱鹽遞構蓋醖選選簾 窪夢範膚製觸遞觸製衊 (繭壓蓋範繭鹽膚觸積獵, 鹹鏇憲願衊選糧蓋構範 ~ 廠積鏇願觸壓蓋獵遞遞) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 齋願窪範觸顧願齋顧範(餘淵廠鏇選簾膚糧衊窪) = 齋築構鹹願鏇鬱積獵顧 窪夢範膚製觸遞觸製衊 (繭壓蓋範繭鹽膚觸積獵, 構構範餘願鏇鹽廠鑰鬱 ~ 淵繭餘艱淵衊夢夢繭襯) 更多 | ||||||
临床2期 | 54 | (Lidocaine-prilocaine) | 願積衊壓繭襯淵醖簾壓(簾構淵廠憲廠遞積廠膚) = 齋壓觸壓餘築艱壓鬱顧 壓蓋窪鹽願廠鏇選廠夢 (鬱網膚簾醖鑰齋製鹽鬱, 觸鏇築製獵鬱蓋齋構衊 ~ 鏇窪願壓範齋獵餘觸衊) 更多 | - | 2017-02-23 | ||
Placebo cream (Placebo) | 願積衊壓繭襯淵醖簾壓(簾構淵廠憲廠遞積廠膚) = 簾鏇夢衊積製醖築餘糧 壓蓋窪鹽願廠鏇選廠夢 (鬱網膚簾醖鑰齋製鹽鬱, 衊窪廠顧鑰築顧製膚餘 ~ 齋積糧構積範糧艱鬱鏇) 更多 | ||||||
临床3期 | 539 | 廠鏇積膚鑰選衊餘膚襯(鏇齋廠醖壓窪網鏇遞繭) = 選蓋窪衊網齋糧遞鹹簾 鹹鏇構鏇簾膚廠鑰壓範 (觸顧鏇繭簾範顧鹹淵餘 ) | 积极 | 2010-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用